117 related articles for article (PubMed ID: 19615725)
1. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.
Pectasides D; Pectasides E; Papaxoinis G; Andreadis C; Papatsibas G; Fountzilas G; Pliarchopoulou K; Macheras A; Aravantinos G; Economopoulos T
Gynecol Oncol; 2009 Oct; 115(1):97-101. PubMed ID: 19615725
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience.
Papadimitriou CA; Peitsidis P; Bozas G; Grimani I; Vlahos G; Rodolakis A; Lianos E; Bamias A; Lainakis G; Dimopoulos MA
Oncology; 2008; 75(1-2):42-8. PubMed ID: 18728371
[TBL] [Abstract][Full Text] [Related]
4. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy.
Kietpeerakool C; Srisomboon J; Phongsaranantakul S; Khunamornpong S; Cheewakriangkrai C; Sribanditmongkol N
J Obstet Gynaecol Res; 2014 Mar; 40(3):806-11. PubMed ID: 24738123
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
7. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
8. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Morris M; Gershenson DM; Burke TW; Kavanagh JJ; Silva EG; Wharton JT
Obstet Gynecol; 1990 Dec; 76(6):1020-4. PubMed ID: 2234710
[TBL] [Abstract][Full Text] [Related]
9. Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases.
Ou YC; Huang HY; Huang CC; Changchien CC; Tseng CW; Lin H
Taiwan J Obstet Gynecol; 2011 Jun; 50(2):141-4. PubMed ID: 21791297
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy.
Pectasides D; Barbounis V; Sintila A; Varthalitis I; Dimitriadis M; Athanassiou A
Am J Clin Oncol; 1994 Feb; 17(1):68-71. PubMed ID: 8311012
[TBL] [Abstract][Full Text] [Related]
11. [Residual Disease Status after Primary Cytoreductive Surgery in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Carcinoma and Long-Term Progression-Free Survival].
Otsuka I; Matsuura T
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2547-2551. PubMed ID: 28028263
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
14. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin.
Cormio G; Maneo A; Gabriele A; Zanetta G; Losa G; Lissoni A
Am J Clin Oncol; 1997 Apr; 20(2):143-5. PubMed ID: 9124187
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
16. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
17. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
18. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
Wagenaar HC; Pecorelli S; Vergote I; Curran D; Wagener DJ; Kobierska A; Bolis G; Bokkel-Huinink WT; Lacave AJ; Madronal C; Forn M; de Oliveira CF; Mangioni C; Nooij MA; Goupil A; Kerbrat P; Marth CH; Tumolo S; Herben MG; Zanaboni F; Vermorken JB
Eur J Gynaecol Oncol; 2001; 22(3):187-93. PubMed ID: 11501769
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
